MHRA-100610-PIP01-22-M01 (update)

Key Facts

Active Substance
Active Substance:
  • ECULIZUMAB
Invented Name
  • SOLIRIS
  • SOLIRIS
PIP Number MHRA-100610-PIP01-22-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentration for solution for infusion
Therapeutic area
Therapeutic area:
  • Neurology
Conditions / Indications
Conditions / Indications:
  • Treatment of myasthenia gravis
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance Check Procedure Number
Compliance procedure number
MHRA-100610-PIP01-22-M01-C

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):ECULIZUMAB.pdf
Published Date 25/05/2023